No CrossRef data available.
Article contents
B-type natriuretic peptide: use and misuse in the older patient
Published online by Cambridge University Press: 09 May 2012
Summary
B-type natriuretic peptide (BNP) and the inactive N-terminal fragment of the precursor (NT-proBNP) are hormones predominantly produced by the cardiac myocyte. It has been shown that very high levels of circulating natriuretic peptides correlate with a diagnosis of heart failure. In view of this, the current NICE, SIGN and European Society of Cardiology guidelines on heart failure recommend the measurement of natriuretic peptides as part of the diagnostic pathway for patients with suspected heart failure in primary care. Patients should be stratified according to results, with high-risk patients referred and reviewed by specialist services within 2 weeks. There has also been interest regarding the potential use of natriuretic peptides in disease surveillance, therapeutic monitoring and in-patient discharge planning. Consequently, it is a test that we will encounter with increasing frequency in clinical practice.
Heart failure is common in older people, hence geriatricians need to have an understanding of the implications of natriuretic peptide levels. The test can be affected by both physiological and pharmacological factors and this should be taken into consideration when interpreting results.
- Type
- Clinical geriatrics
- Information
- Copyright
- Copyright © Cambridge University Press 2012
References
1National Heart Failure Report April 2010–March 2011. Available at: http://www.ucl.ac.uk/nicor/audits/heartfailure/ (accessed 9 April 2012).Google Scholar
2British Heart Foundation Health Promotion Research Group. Coronary heart disease statistics: 2010 edition. Department of Public Health, University of Oxford, 2010, p. 54.Google Scholar
3NICE. Chronic heart failure: Management of chronic heart failure in adults in primary and secondary care. London, NICE, 2010. Available at: http://publications.nice.org.uk/chronic-heart-failure-cg108 (accessed 9 April 2012).Google Scholar
4Kisch, B. Electron microscopy of the atrium of the heart. I. Guinea pig. Exp Med Surg 1956; 14: 99–112.Google ScholarPubMed
5de Bold, AJ, Borenstein, HB, Veress, AT, Sonnenberg, H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89–94.CrossRefGoogle ScholarPubMed
6Sudoh, T, Kangawa, K, Minamino, N, Matsuo, H. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78–81.CrossRefGoogle ScholarPubMed
7Doust, JA, Glasziou, PP, Pietrzak, E, Dobson, AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004; 164: 1978–84.CrossRefGoogle ScholarPubMed
9Clerico, A, Recchia, FA, Passino, C, Emdin, M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006; 290: H17–29.CrossRefGoogle ScholarPubMed
10Felker, GM, Petersen, JW, Mark, DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 2006; 175: 611–17.CrossRefGoogle ScholarPubMed
11Holmes, SJ, Espiner, EA, Richards, AM, Yandle, TG, Frampton, C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76: 91–96.Google ScholarPubMed
12Mair, J, Friedl, W, Thomas, S, Puschendorf, B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl 1999; 230: 132–42.CrossRefGoogle ScholarPubMed
13Clerico, A, Fontana, M, Zyw, L, Passino, C, Emdin, M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007; 53: 813–22.CrossRefGoogle ScholarPubMed
14Raymond, I, Groenning, BA, Hildebrandt, PR, Nisson, JC, Baumann, M, Trawinski, J, Pedersen, F. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89: 745–51.CrossRefGoogle Scholar
15Maisel, A, Mueller, C, Adams, K Jr, Anker, SD, Aspromonte, N, Cleland, JG, Cohen-Solal, A, Dahlstrom, U, DeMaria, A, Di Somma, S, Filippatos, GS, Fonarow, GC, Jourdain, P, Komajda, M, Liu, PP, McDonagh, T, McDonald, K, Mebazaa, A, Nieminen, MS, Peacock, WF, Tubaro, M, Valle, R, Vanderhyden, M, Yancy, CW, Zannad, F, Braunwald, E. State of the art: Using natriutetic peptide levels in clinical practice. Eur J Heart Failure 2008; 10: 824–39.CrossRefGoogle Scholar
16Mark, PB, Stewart, GA, Gansevoort, RT, Petrie, CJ, McDonagh, TA, Dargie, HJ, Rodger, RS, Jardine, AG. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant 2006; 21: 402–10.CrossRefGoogle ScholarPubMed
17van Kimmenade, RR, Januzzi, JL Jr, Bakker, JA, Houben, AJ, Rennenberg, R, Kroon, AA, Crijns, HJ, van Dieijen-Visser, MP, de Leeuw, PW, Pinto, YM. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide: a mechanistic study in hypertensive subjects. J Am Coll Cardiol 2009; 53: 884–90.CrossRefGoogle ScholarPubMed
18Krauser, DG, Lloyd-Jones, DM, Chae, CU, Cameron, R, Anwaruddin, S, Baggish, AL, Chen, A, Tung, R, Januzzi, JL Jr. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) substudy. Am Heart J 2005; 149: 744–50.CrossRefGoogle ScholarPubMed
19Bettencourt, P. NTproBNP and BNP: biomarkers for heart failure management. Eur J Heart Failure 2004; 6: 359–63.CrossRefGoogle ScholarPubMed
20Cowie, MR, Collinson, PO, Dargie, H et al. Recommendations on the clinical use of B-type natriuretic peptide testing (BNP or NTproBNP) in the UK and Ireland. Br J Cardiol 2010; 17: 76–80.Google Scholar
21Dickstein, K, Cohen-Solal, A, Filippatos, G, McMurray, JJ, Ponikowski, P, Poole-Wilson, PA, Strömberg, A, van Veldhuisen, DJ, Atar, D, Hoes, AW, Keren, A, Mebazaa, A, Nieminen, M, Priori, SG, Swedberg, K; ESC Committee for Practice Guidelines (CPG). European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2008; 29: 2388–442.Google Scholar
22Pfisterer, M, Buser, P, Rickli, H, Gutmann, M, Erne, P, Rickenbacher, P, Vuillomenet, A, Jeker, U, Dubach, P, Beer, H, Yoon, SI, Suter, T, Osterhues, HH, Schieber, MM, Hilti, P, Schindler, R, Brunner-La Rocca, HP; TIME-CHF Investigators. The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial. JAMA 2009; 37: 386–91.Google Scholar
23Lainchbury, JG, Troughton, RW, Strangman, KM, Frampton, CM, Pilbrow, A, Yandle, TG, Hamid, AK, Nicholls, MG, Richards, AM. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure results from the BATTLESCARRED (NT-proBNP–Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2010; 55: 53–60.CrossRefGoogle Scholar
24Bettencourt, P, Azevedo, A, Pimenta, J, Friões, F, Ferreira, S, Ferreira, A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168–74.CrossRefGoogle ScholarPubMed
25Logeart, D, Thabut, G, Jourdain, P, Chavelas, C, Beyne, P, Beauvais, F, Bouvier, E, Solal, AC. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635–641.CrossRefGoogle ScholarPubMed